We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Modeling Genetic Circuitry of Cell-To-Cell Communication with Integrated Fluid Circuit Technology

By LabMedica International staff writers
Posted on 26 Aug 2010
Print article
Utilizing integrated fluidic circuits (IFCs), researchers have discovered a much larger spectrum of differences between individual cells than has previously been demonstrated. Among these differences are the communication capabilities that emerge from the interactions of genetic circuitry that mediates cell-to-cell communication.

Stanford University (Palo Alto, CA, USA) investigators used Fluidigm Corporation's (South San Francisco, CA, USA) Dynamic Array and Digital Array technology in addition to support instrumentation for its cell culture chip as part of this innovative analysis and modeling on how biologic systems operate at the cellular level.

Stanford University School of Medicine found that, "Cells don't all act in a uniform fashion, as was previously thought. Think of cells as musicians in a jazz band,” said Marcus Covert, Ph.D., assistant professor of bioengineering and senior author of the study, published online in the journal Nature June 27, 2010. Dr. Covert's lab studies complex genetic systems. "One little trumpet starts to play, and the cells go off on their own riffs. One plays off of the other.”

Up to now, most of the scientific data collected on cell signaling has been obtained from populations of cells using bulk assays due to technologic limitations on the ability to examine each individual cell. The new study, using an imaging system developed at Stanford based on microfluidics, revealed that scientists have been misled by the results of the cell-population-based studies, according to the researchers.

"This study represents a triple-play of Fluidigm capabilities. Steve, Markus, and their teams used Fluidigm's Dynamic Arrays and Digital Arrays chips for a large portion of their work and some of our analytical instrumentation in operating the cell culture chip. Their work with cell culture coincides with development work that Fluidigm has underway to develop a Stem Cell Culture Chip for the commercial market under a grant from CIRM [California Institute of Regenerative Medicine],” said Gajus Worthington, president and chief executive officer of Fluidigm.

Fluidigm provides commercially available technology on the market to examine individual cells. This technology enabled these Stanford researchers to look at thousands of individuals cells and conduct a multitude of tests on each cell. Fluidigm researchers said, "Population studies have not revealed the intricate network of information one observes at the single-cell level.

"This really surprised us,” said study coauthor Stephen Quake, Ph.D., a professor of bioengineering at Stanford, and a leader in the field of microfluidics. "It sends us back to the drawing board to figure out what is really going on in cells.”

The study used a combination of Fluidigm 48.48 Dynamic Array IFCs to perform 2,304 quantitative polymerase chain reactions (qPCR) in parallel per chip. The cycle thresholds measured during qPCR reactions were converted into relative expression levels and those expression levels were calibrated for total mRNA molecules per cell using Fluidigm Digital Array IFCs performing digital PCR measurements on a single gene.

"These results highlight the value of high-throughput, quantitative measurements, with single-cell resolution in understanding how biological systems operate. We couldn't agree more,” said Fred Walder, Fluidigm's chief business officer. "The Fluidigm platform is uniquely matched to this emerging and critical biological research reality. As more scientists discover that single-cell understanding is key to life science research, we anticipate dramatically increasing interest and demand for our IFC platform products.”

Fluidigm develops, manufactures, and markets proprietary IFC systems that significantly improve productivity in life science research. Fluidigm IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These "integrated circuits for biology” are made possible by miniaturizing and integrating liquid-handling components on a single microfluidic device.

Related Links:

Stanford University
Fluidigm


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Ultrasound-based duplex sonography combined with a new genetic testing procedure can identify clonal haematopoiesis (Photo courtesy of 123RF)

New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk

A key interest area in cardiovascular research today is the impact of clonal hematopoiesis on cardiovascular diseases. Clonal hematopoiesis results from mutations in hematopoietic stem cells and may lead... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.